NICE recommends new chemotherapy-free treatment option for people with untreated chronic lymphocytic leukaemia
More than 1,000 people each year will benefit from NICE's recommendation
Search results
1247 results
-
-
NICE's methods of technology evaluation - presenting a case for change
NICE has today (6 November 2020) launched a public consultation on proposals for changes to the methods it uses to develop its guidance on medicines, medical devices and diagnostics.
-
NICE to become single point of access for Covid-19 guidance and advice
NICE has today (6 November) announced that it is to host a new, single point of advice on caring for people with Covid-19 and the management of Covid-19 in a variety of clinical settings.
-
Skin cancer drug not cost effective for routine NHS use
A consultation on the draft recommendations has now begun until Tuesday 24 November 2020
-
Shared Learning Awards 2020 finalist: Bronchiolitis: when less is more
The Shared Learning Awards recognise the brilliant work being done to put NICE guidance and standards into practice in a range of organisations, including NHS, local authorities, and the voluntary sector. The following work has been shortlisted for the NICE Shared Learning Awards 2020 and represents one of our 3 finalists.
-
Shared Learning Awards 2020 finalist: East of England Stroke Telemedicine Partnership
The Shared Learning Awards recognise the brilliant work being done to put NICE guidance and standards into practice in a range of organisations, including NHS, local authorities, and the voluntary sector. The following work has been shortlisted for the NICE Shared Learning Awards 2020 and represents one of our three finalists.
-
NICE recommends new treatment option for adults with obesity and non-diabetic hyperglycaemia who have a high risk of cardiovascular disease
All eligibility criteria must be met for Liraglutide to be offered
-
NICE, SIGN and RCGP set out further details about the UK guideline on management of the long-term effects of COVID-19
NICE, the Scottish Intercollegiate Guidelines Network (SIGN) and the Royal College of General Practitioners (RCGP) have today (30 October 2020) given more details about the forthcoming guideline on post-COVID syndrome.
-
Shared Learning Awards 2020 finalist: Prescribing guidelines for patients with a first episode psychosis
The Shared Learning Awards recognise the brilliant work being done to put NICE guidance and standards into practice in a range of organisations, including the NHS, local authorities, and the voluntary sector. The following work has been shortlisted for the NICE Shared Learning Awards 2020 and represents one of our three finalists.
-
NICE announces start of review of nusinersen Managed Access Agreement
NICE has today (29 October 2020) announced that it has begun the process to review data collected as part of the Managed Access Agreement (MAA) for nusinersen (also called Spinraza and made by Biogen) for treating the rare genetic disorder spinal muscular atrophy (SMA).
-
Test people with womb cancer for inherited genetic condition, NICE says in new guidance
Research led by Professor Emma Crosbie, with Professor Gareth Evans and Dr Neil Ryan from The University of Manchester and Manchester University NHS Foundation Trust, showed the benefits of different testing strategies for Lynch syndrome in womb cancer cases in increasing diagnosis of the condition.
-
Inside NICE: My experience of the scholarship programme
Howard Ryland, National Institute of Health Research (NIHR) Doctoral Research Fellow at the Department of Psychiatry at the University of Oxford, discusses his experience as a NICE scholar.
-
NICE gears up to support World Evidence-based Healthcare Day
Inaugural World Evidence-based Healthcare (EBHC) Day takes place on Tuesday 20 October 2020
-
NICE draft guidance recommends siponimod for treating secondary progressive multiple sclerosis
NICE has today (15 October 2020) issued draft guidance which now recommends siponimod (also called Mayzent and made by Novartis) for treating secondary progressive multiple sclerosis (MS).
-
World Evidence-Based Healthcare Day: Using evidence to inform our recommendations
Dr Martin Allaby discusses World Evidence-Based Healthcare Day and how NICE uses evidence to inform our recommendations.
-
Evidence for HTA: Innovative methods for challenging times
Dalia Dawoud, Scientific Adviser at NICE Science, Evidence and Analytics Directorate explains NICE’s role as co-host of HTAi 2021 in the UK
-
NICE non-executive director Elaine Inglesby-Burke CBE awarded Damehood for services to nursing
Elaine has been honoured in the Queen’s birthday honours list to recognise her commitment to the profession
-
NICE proposes simplifying how medicines and medical devices are selected for evaluation.
As part of the work underway to review the methods and processes NICE uses to develop guidance on medicines, medical devices and diagnostics, NICE has launched a public consultation on proposals for changing how it selects the topics it will develop guidance on.
-
NICE & SIGN announce latest rapid Covid-19 guideline will address Long Covid
NICE and the Scottish Intercollegiate Guidelines Network (SIGN) have today (5 October 2020) announced they will work with the Royal College of General Practitioners (RCGP) to develop a guideline on persistent effects of Covid-19 (Long Covid) on patients.
-
NICE board agrees to stimulate action following publication of Independent Medicines and Medical Devices Safety Review report
NICE to reinforce the importance of collaborative working with system partners to ensure a more integrated approach to safety recommendations made in NICE guidance
-
NICE announces autumn series of virtual events
Three webinar style events will feature a number of high-profile speakers
-
NICE joins global alliance to shine spotlight on evidence-based healthcare
Tuesday 20 October will be the inaugural World Evidence-based Healthcare Day
-
NICE's support for rebuilding capacity in non-COVID health services
Director of our Centre for Guidelines, Paul Chrisp, discusses how NICE can help the NHS and wider care sector restore services most affected by the COVID-19 pandemic
-
Call for abstracts for HTAi 2021 Annual Meeting in Manchester
Health Technology Assessment International (HTAi) has released the plenary themes for the HTAi 2021 Annual Meeting and opened their call for abstract submissions
-
NICE chief executive and chairman thank non-executive director for his service as he announces resignation
Professor Martin Cowie stands down from the NICE board following his appointment to a role at Astra Zeneca
-
Improved agreement means NICE now recommends lung cancer treatment
Thousands of people with non-small-cell lung cancer (NSCLC) will benefit from draft guidance published today by NICE.
-
Feeling safe and being heard in residential care is crucial
Dorothy Hodgkinson from Finding Perspectives discusses the importance of safeguarding adults in care homes
-
Nasal spray medicine for treatment-resistant depression not recommended by NICE
Consultation open on draft guidance until Friday 25 September 2020
-
Be aware of the signs of abuse and neglect in adult care homes, says NICE
Staff and visitors can play a vital role in the identification and prevention of abuse and neglect in care homes for adults says NICE, in a draft guideline published today.
-
Recruitment begins to fill up to seven non-executive roles on the NICE board
Roles will contribute to the development of NICE’s strategic objectives
-
New agreement means NICE recommends combination treatment for some lymphoma patients
Hundreds of people with a form of blood cancer will benefit from a new treatment following the publication of draft guidance by NICE.
-
NICE extends consultation period for new quality standard on fetal alcohol spectrum disorder
NICE has today (20 August, 2020), released its draft quality standard on fetal alcohol spectrum disorder (FASD) for further public consultation.
-
NICE appoints two directors to key new positions
NICE has announced the appointment of two new directors to key positions in newly formed directorates.
-
Commonly used treatments for chronic pain can do more harm than good and should not be used, says NICE in draft guidance
A number of commonly used drug treatments for chronic primary pain have little or no evidence that they work and shouldn’t be prescribed, NICE has said in its draft clinical guideline published today (3 August 2020) on the assessment and management of chronic pain in over 16s.
-
New combination treatment for patients with advanced kidney cancer
Adults with advanced renal cell carcinoma can now be offered avelumab with axitinib as a first line treatment option on the Cancer Drugs Fund (CDF), NICE has said in final draft guidance.
-
NICE publishes new COVID-19 rapid guideline on arranging planned care in hospitals and diagnostic services
NICE has today (27 July 2020) published a guideline on the arrangements the NHS should put in place for patients needing elective surgery and other planned treatments and procedures (including diagnostics and imaging) during the COVID-19 pandemic.
-
NICE signs agreement with Colombia's Institute of Health Technology Assessment to forge closer working ties
Research and knowledge sharing key to collaborative working approach agreed the two agencies
-
NICE's strategy on sustainability: current progress and next steps
Fizzah Ali, NICE clinical fellow, outlines the key steps towards a sustainability strategy at NICE
-
Innovation through HTA: theme for HTAi 2021 Annual Meeting announced
Health Technology Assessment International (HTAi) has announced the theme for the 2021 Annual Meeting which will be held from 19-23 June in Manchester.
-
NICE draft guidance does not recommend siponimod for treating secondary progressive multiple sclerosis
NICE has today (25 June 2020) issued draft guidance for public consultation which does not recommend siponimod (also called Mayzent and made by Novartis) for treating secondary progressive multiple sclerosis (MS).
-
Cancer patients to benefit from new histology independent treatment
Entrectinib (Rozlytrek, Roche), a revolutionary treatment for a range of cancers, is the second histology independent drug to be recommended by NICE for use on the Cancer Drugs Fund (CDF).
-
NICE begins phased restart of non-COVID-19 guidance
NICE has begun a phased restart of publishing non-COVID-19 guidance as the NHS and wider health and care system start to return to normal arrangements.
-
Steam treatment recommended for men with an enlarged prostate
Minimally invasive procedure involves injecting steam to destroy excess prostate tissue
-
NICE publishes latest COVID-19 guidance on renal transplantation
NICE has published new rapid COVID-19 guidance for children, young people and adults who need or who have had a kidney transplant, and people who are donating a kidney (live donors).
-
NICE recommends treatment for type of small-cell lung cancer
A new treatment option for patients with extensive-stage small-cell lung cancer has been approved by NICE.
-
NICE chairman Sharmila Nebhrajani begins her new role
NICE is delighted to announce that today (26 May 2020) Sharmila Nebhrajani, OBE, has taken up her position as its new chairman following her appointment by the Secretary of State for Health and Social Care and an independent open recruitment process.
-
Improved deal means new treatment for a type of advanced breast cancer can be recommended by NICE
Draft guidance published today (22 May 2020) by NICE recommends atezolizumab for treating people with a type of breast cancer, called triple negative breast cancer, that has spread to other parts of the body.
-
NICE publishes rapid COVID-19 guidelines on chronic kidney disease and interstitial lung disease
NICE has today (15 May) published 2 new rapid COVID-19 guidelines. The first is on chronic kidney disease (CKD) and the second on interstitial lung disease.
-
NICE draft guidance recommends new treatment option for people with early breast cancer
NICE has today (7 May 2020) published draft guidance which recommends trastuzumab emtansine (also called Kadcyla and made by Roche) as an option for some people with HER2-positive early breast cancer.
-
New COVID-19 guideline on acute kidney injury
NICE has published a new COVID-19 rapid guideline on acute kidney injury (AKI).